The IL-6 cytokine family has attracted much attention due to its association with the promotion of immunosuppression of the TME in cancers as a proinflammatory factor (42), and current research on IL-6 family-related therapeutic targets has established that agents targeting IL-6 or the IL-6 receptor not only directly inhibit the growth of tumor cells, but also exerts synergistic effects with tumor immunotherapy. This evidence concerns the gene IL6 and neoplasm.